{"id":"next-line-ibrutinib","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Diarrhea"},{"rate":"40-50","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Bruising/bleeding"},{"rate":"25-40","effect":"Infection"},{"rate":"5-10","effect":"Atrial fibrillation"},{"rate":"15-25","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibrutinib irreversibly binds to and inhibits BTK, a key enzyme in the B-cell receptor signaling pathway. This inhibition prevents B-cell activation, proliferation, and migration, making it effective against B-cell malignancies. The drug also has activity against other kinases including TEC family kinases, contributing to its broader immunomodulatory effects.","oneSentence":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:01.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Mantle cell lymphoma (MCL)"},{"name":"Marginal zone lymphoma (MZL)"},{"name":"Waldenström macroglobulinemia (WM)"}]},"trialDetails":[{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT03198026","phase":"PHASE2","title":"Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-02-20","conditions":"Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma","enrollment":30},{"nctId":"NCT04694560","phase":"","title":"A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-22","conditions":"CLL, SLL, CLL/SLL","enrollment":""},{"nctId":"NCT02232386","phase":"PHASE2","title":"Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2015-03-02","conditions":"Chronic Lymphocyte Leukemia, Adult Patients","enrollment":156},{"nctId":"NCT01724346","phase":"PHASE3","title":"Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-12-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":269},{"nctId":"NCT03624036","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"Kite, A Gilead Company","startDate":"2018-11-15","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma","enrollment":16},{"nctId":"NCT02623010","phase":"PHASE2","title":"Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2016-10","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT04639362","phase":"PHASE2","title":"CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2020-12-29","conditions":"CLL","enrollment":85},{"nctId":"NCT03265717","phase":"PHASE2","title":"DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Invectys","startDate":"2018-07-25","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PCI-32765"],"phase":"phase_3","status":"active","brandName":"Next-line ibrutinib","genericName":"Next-line ibrutinib","companyName":"Pharmacyclics LLC.","companyId":"pharmacyclics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}